These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 31828474)

  • 1. Frequency and clinical features of treatment-refractory myasthenia gravis.
    Rath J; Brunner I; Tomschik M; Zulehner G; Hilger E; Krenn M; Paul A; Cetin H; Zimprich F
    J Neurol; 2020 Apr; 267(4):1004-1011. PubMed ID: 31828474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
    Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
    Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late-onset generalized myasthenia gravis: clinical features, treatment, and outcome.
    Yildiz Celik S; Durmus H; Yilmaz V; Saruhan Direskeneli G; Gulsen Parman Y; Serdaroglu Oflazer P; Deymeer F
    Acta Neurol Belg; 2020 Feb; 120(1):133-140. PubMed ID: 31811563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis.
    Brauner S; Eriksson-Dufva A; Hietala MA; Frisell T; Press R; Piehl F
    JAMA Neurol; 2020 Aug; 77(8):974-981. PubMed ID: 32364568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors affecting outcome in ocular myasthenia gravis.
    Mazzoli M; Ariatti A; Valzania F; Kaleci S; Tondelli M; Nichelli PF; Galassi G
    Int J Neurosci; 2018 Jan; 128(1):15-24. PubMed ID: 28625092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with maintenance therapeutic plasma exchange in refractory generalized myasthenia gravis.
    Sheckley H; Malhotra K; Katyal N; Narula N; Govindarajan R
    J Clin Apher; 2021 Oct; 36(5):727-736. PubMed ID: 34241920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline Decrement in Patients with Mild Myasthenia Gravis Predicts Immunomodulation Treatment.
    Abraham A; Lovblom LE; Bril V
    Can J Neurol Sci; 2019 Nov; 46(6):762-766. PubMed ID: 31322098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis of Ocular Myasthenia Gravis: Retrospective Multicenter Analysis.
    Nagia L; Lemos J; Abusamra K; Cornblath WT; Eggenberger ER
    Ophthalmology; 2015 Jul; 122(7):1517-21. PubMed ID: 25892018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance plasma exchange treatment for muscle specific kinase antibody positive myasthenia gravis patients.
    Yamada C; Teener JW; Davenport RD; Cooling L
    J Clin Apher; 2015 Oct; 30(5):314-9. PubMed ID: 25557356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
    Kupersmith MJ; Latkany R; Homel P
    Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Periodic therapeutic plasma exchange in patients with moderate to severe chronic myasthenia gravis non-responsive to immunosuppressive agents: an eight year follow-up.
    Triantafyllou NI; Grapsa EI; Kararizou E; Psimenou E; Lagguranis A; Dimopoulos A
    Ther Apher Dial; 2009 Jun; 13(3):174-8. PubMed ID: 19527462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Employment in refractory myasthenia gravis: A Myasthenia Gravis Foundation of America Registry analysis.
    Harris L; Aban IB; Xin H; Cutter G
    Muscle Nerve; 2019 Dec; 60(6):700-706. PubMed ID: 31478207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
    Katyal N; Narula N; Govindarajan R
    J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Juvenile myasthenia gravis in Norway: Clinical characteristics, treatment, and long-term outcome in a nationwide population-based cohort.
    Popperud TH; Boldingh MI; Rasmussen M; Kerty E
    Eur J Paediatr Neurol; 2017 Sep; 21(5):707-714. PubMed ID: 28457757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A series of patients with refractory myasthenia gravis.
    Garcia-Garcia J; Díaz-Maroto I; Martínez-Martín A; Pardal-Fernández JM; Segura T
    Neurologia (Engl Ed); 2023 May; 38(4):256-261. PubMed ID: 37031801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early-onset myasthenia gravis: clinical characteristics and response to therapy.
    Batocchi AP; Evoli A; Palmisani MT; Lo Monaco M; Bartoccioni M; Tonali P
    Eur J Pediatr; 1990 Nov; 150(1):66-8. PubMed ID: 2079081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous cyclophosphamide monthly pulses in refractory myasthenia gravis.
    Gomez-Figueroa E; Garcia-Trejo S; Bazan-Rodriguez L; Cervantes-Uribe R; Chac-Lezama G; López-Hernández JC; Vargas-Cañas S
    J Neurol; 2020 Mar; 267(3):674-678. PubMed ID: 31720821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome.
    Cortés-Vicente E; Álvarez-Velasco R; Pla-Junca F; Rojas-Garcia R; Paradas C; Sevilla T; Casasnovas C; Gómez-Caravaca MT; Pardo J; Ramos-Fransi A; Pelayo-Negro AL; Gutiérrez-Gutiérrez G; Turon-Sans J; López de Munain A; Guerrero-Sola A; Jericó I; Martín MA; Mendoza MD; Morís G; Vélez-Gómez B; Garcia-Sobrino T; Pascual-Goñi E; Reyes-Leiva D; Illa I; Gallardo E
    Ann Clin Transl Neurol; 2022 Feb; 9(2):122-131. PubMed ID: 35080153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical profile and impact of comorbidities in patients with very-late-onset myasthenia gravis.
    Vijayan J; Menon D; Barnett C; Katzberg H; Lovblom LE; Bril V
    Muscle Nerve; 2021 Oct; 64(4):462-466. PubMed ID: 34235762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival, Prognosis, and Clinical Feature of Refractory Myasthenia Gravis: a 15-year Nationwide Cohort Study.
    Jeong S; Noh Y; Oh IS; Hong YH; Shin JY
    J Korean Med Sci; 2021 Oct; 36(39):e242. PubMed ID: 34636500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.